BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Datamonitor Release: AMNOG May Cause Havoc in German Diabetes Market - Analyst Opinion


7/9/2013 10:08:08 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!



July 09, 2013 -- Text Expert analyst opinion on the impact of AMNOG, Germany’s Pharmaceutical Market Reorganization Act, on future diabetic therapies and leading diabetes players including Bristol-Myers Squibb/AstraZeneca, Novartis, and Merck & Co. Bristol-Myers Squibb/AstraZeneca, Novartis, and Merck & Co could soon have to drop the prices of their dipeptidyl peptidase-IV (DPP-IV) inhibitors Onglyza (saxagliptin), Galvus (vildagliptin), and Januvia (sitagliptin) in Germany if health technology appraisal bodies there remain less than impressed. The products are undergoing the first retrospective review under Germany’s tough Pharmaceutical Market Reorganization Act (AMNOG; Arzneimittelmarktneuordungsgesetz) pricing and reimbursement system, and the Institute for Quality and Efficiency in Healthcare (IQWiG; Institut für Qualitat und Wirtschaftlichkeit im Gesundheitswesen) released its preliminary findings on 1 July 2013.

Pricing in Germany matters not only because it is one of Europe’s biggest markets, but also because a number of other European countries reference prices there. Therefore, price cuts in Germany could eventually lead to reductions elsewhere and impact significantly on company revenues.

Read on here...

Datamonitor Healthcare

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES